Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Myeloid supressor cells

ASH 2009

Published: 27 Jan 2010

Views: 8490

Rating:

Save

Prof John Harlan - University of Washington, USA

Prof John Harlan talks about the latest in myeloid supressor cells and adapting immune response by targeting the tumour micro-environment.

Categories:
Haematology oncology

Related Videos

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and...

Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects ( Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal )

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma...

Dr Jonathan Friedberg - University of Rochester, Rochester, USA

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy ( Dr Jonathan Friedberg - University of Rochester, Rochester, USA )

Management of multiple myeloma in a resource-constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Management of multiple myeloma in a resource-constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Significant clinical benefits observed with revumenib monotherapy in relapsed...

Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA

$Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia ( Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA )$

Ide-cell enhances health-related quality of life for refractory multiple myeloma

Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium

$Ide-cell enhances health-related quality of life for refractory multiple myeloma ( Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium )$

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B...

Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany

Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B-cell lymphoma ( Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany )

Beat AML master trial: A clinical trial for acute myeloid leukaemia

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA

Beat AML master trial: A clinical trial for acute myeloid leukaemia ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )

More from ecancer